nach oben

Erschienen in:

01.08.2006 | Original Research

Risk Reduction Behaviors and Provider Communication Following Genetic Counseling and BRCA1 Mutation Testing in an African American Kindred

verfasst von: Anita Yeomans Kinney, Sara Ellis Simonsen, Bonnie Jeanne Baty, Diptasri Mandal, Susan L. Neuhausen, Kate Seggar, Richard Holubkov, Lindsey Bloor, Ken Smith

Erschienen in: Journal of Genetic Counseling | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Little is known about the impact of cancer genetic counseling and testing on health behaviors in racial and ethnic subgroups. This prospective observational study examined use of risk reduction strategies following BRCA1 counseling and testing. Participants were female members of an African American kindred who received genetic education, counseling and testing (n = 40) and completed a 1-year follow-up interview. Mutation carriers were more likely to opt for breast (100%, 7/7) and ovarian (25%; 1 of 4) cancer surveillance than prophylactic surgery. Following genetic counseling, 71% (5/7) of the BRCA1 carriers who opted for surveillance reported having a mammogram within the year following receipt of their genetic test results. Ovarian cancer screening among mutation carriers increased from 0% at baseline to 25% (one of four) at 1 year. Compared to noncarriers (23%, 7/30), carriers (70%, 7/10) were more likely to discuss their BRCA1 test results with their primary health care providers. Surveillance for breast cancer was preferred to prophylactic surgery and chemoprevention as a way to reduce risk for these cancers. Our data indicate that patient-provider communication about BRCA1 test results is suboptimal.

Ahmed, N. U., Fort, J. G., Elzey, J. D., & Bailey, S. (2004). Empowering factors in repeat mammography: Insights from the stories of underserved women. J Ambul Care Manage, 27, 348–355.PubMed

Ahmed, N. U., Fort, J. G., Elzey, J. D., & Belay, Y. (2005). Empowering factors for regular mammography screening in under-served populations: Pilot survey results in Tennessee. Ethn Dis, 15, 387–394.PubMed

American Cancer Society (2004). Cancer facts and figures 2004. Atlanta, GA: American Cancer Society.

Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, A., Pasini, B., Radice, P., Manoukian, S., Eccles, D. M., Tang, N., Olah, E., Anton-Culver, H., Warner, E., Lubinski, J., Gronwald, J., Gorski, B., Tulinius, H., Thorlacius, S., Eerola, H., Nevanlinna, H., Syrjakoski, K., Kallioniemi, O. P., Thompson, D., Evans, C., Peto, J., Lalloo, F., Evans, D. G., & Easton, D. F. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet, 72, 1117–1130.

Baty, B. J., Kinney, A. Y., & Ellis, S. M. (2003). Developing culturally sensitive cancer genetics communication aids for African Americans. Am J Med Genet, 118A, 146–155.CrossRefPubMed

Botkin, J. R., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., Chan, A., Hamann, H. A., Lerman, C., McDonald, J., Venne, V., Ward, J. H., & Lyon, E. (2003). Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet, 118A, 201–209.CrossRefPubMed

Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J., Lynch, P., McTiernan, A., Offit, K., Perlman, J., Petersen, G., Thompson, E., & Varricchio, C. (1997). Recommendations for follow-up care of individuals with an inherited predisposition to breast cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA, 277, 997–1003.PubMedCrossRef

Caplan, L. S., McQueen, D. V., Qualters, J. R., Leff, M., Garrett, C., & Calonge, N. (2003). Validity of women's self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiol Biomark Prev, 12, 1182–1187.

Centers for Disease Control, N. C. F. H. S. (2002). Use of mammography for women 40 years of age and older, according to selected characteristics: Selected years, 1987–2000. internet [On-line]. Available at http://seer.cancer.gov/csr/1972_1999/breast.pdf.

Champion, V. L., Menon, U., McQuillen, D. H., & Scott, C. (1998). Validity of self-reported mammography in low-income African-American women 13. Am J Prev Med, 14, 111–117.PubMedCrossRef

Corbie-Smith, G., Frank, E., & Nickens, H. (2000). The intersection of race, gender, and primary care: Results from the Women Physicians’ Health Study. J Natl Med Assoc, 92, 472–480.PubMed

Davis, C., Emerson, J. S., & Husaini, B. A. (2005). Breast cancer screening among African American women: Adherence to current recommendations. J Health Care Poor Underserved, 16, 308–314.PubMedCrossRef

Domchek, S. M., Eisen, A., Calzone, K., Stopfer, J., Blackwood, A., & Weber, B. L. (2003). Application of breast cancer risk prediction models in clinical practice. J Clin Oncol, 21, 593–601.PubMedCrossRef

Dormon, J. H. (1992). Louisiana's ‘Creoles of color’: Ethnicity, marginality, and identity. Soc Sci Q, 73, 615–627.

Dubois, S., & Melancon, M. (2000). Creole is, Creole ain’t: Diachronic and synchronic attitudes toward Creole identity in southern Louisiana. Language in Society, 29, 237–258.CrossRef

Eisen, A., & Weber, B. L. (2001). Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations—Facts and controversy. N Engl J Med, 345, 207–208.PubMedCrossRef

Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., Sobol, H., Teare, M. D., Struewing, J., Arason, A., Scherneck, S., Peto, J., Rebbeck, T. R., Tonin, P., Neuhausen, S., Barkardottir, R., Eyfjord, J., Lynch, H., Ponder, B. A., Gayther, S. A., & Zelada-Hedman, M. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet, 62, 676–689.PubMedCrossRef

Frank, T. S., & Critchfield, G. C. (2002). Hereditary risk of women's cancers. Best Pract Res Clin Obstet Gynaecol, 16, 703–713.PubMedCrossRef

Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hullick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., & Critchfield, G. C. (2002). Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol, 20, 1480–1490.PubMedCrossRef

Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood, M. E., Mullineau, L., Isaacs, C., Peshkin, B., Buys, S., Venne, V., Rowley, P. T., Loader, S., Offit, K., Robson, M., Hampel, H., Brener, D., Winer, E. P., Clark, S., Weber, B., Strong, L. C., & Thomas, A. (1998). Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol, 16, 2417–2425.PubMed

Gao, Q., Neuhausen, S., Cummings, S., Luce, M., & Olopade, O. I. (1997). Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet, 60, 1233–1236.PubMed

Gao, Q., Tomlinson, G., Das, S., Cummings, S., Sveen, L., Fackenthal, J., Schumm, P., & Olopade, O. I. (2000). Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet, 107, 186–191.PubMedCrossRef

Glanz, K., Croyle, R. T., Chollette, V. Y., & Pinn, V. W. (2003). Cancer-related health disparities in women. Am J Public Health, 93, 292–298.PubMedCrossRef

Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., McDonnell, S. K., Vockley, C. W., Deffenbaugh, A., Cough, F. J., & Jenkins, R. B. (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 93, 1633–1637.PubMedCrossRef

Herek, G. M., Gillis, J. R., Glunt, E. K., Lewis, J., Welton, D., & Capitanio, J. P. (1998). Culturally sensitive AIDS educational videos for African American audiences: Effects of source, message, receiver, and context. Am J Community Psychol, 26, 705–743.PubMedCrossRef

Isaacs, C., Peshkin, B. N., Schwartz, M., Demarco, T. A., Main, D., & Lerman, C. (2002). Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Res Treat, 71, 103–112.PubMedCrossRef

Jones, B. A., Patterson, E. A., & Calvocoressi, L. (2003). Mammography screening in African American women: Evaluating the research. Cancer, 97, 258–272.PubMedCrossRef

Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., Norton, L., Castiel, M., Nafa, K., & Offit, K. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med, 346, 1609–1615.PubMedCrossRef

Kinney, A. Y., Bloor, L. E., Mandal, D., Simonsen, S. E., Baty, B. J., Holubkov, R., Seggar, K., Neuhausen, S., & Smith, K. (2005). The impact of receiving genetic test results on general and cancer-specific psychologic distress among members of an African-American kindred with a BRCA1 mutation. Cancer, 104, 2508–2516.PubMedCrossRef

Kinney, A. Y., Simonsen, S. E., Baty, B. J., Mandal, D., Neuhausen, S. L., Seggar, K., Holubkov, R., & Smith, K. (2006). Acceptance of genetic testing for hereditary breast ovarian cancer among study enrollees from an African American kindred. Am J Med Genet A, 140, 813–826.

Klaren, H. M., van't Veer, L. J., van Leeuwen, F. E., & Rookus, M. A. (2003). Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst, 95, 941–947.PubMedCrossRef

Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33, 159–174.PubMedCrossRef

Lerman, C., Hughes, C., Croyle, R. T., Main, D., Durham, C., Snyder, C., Bonney, A., Lynch, J. F., Narod, S. A., & Lynch, H. T. (2000). Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med, 31, 75–80.PubMedCrossRef

Littell, R. C., Milliken, G. A., Stroup, W. W., & Wolfinger, R. (1996). SAS system for mixed models. Cary, NC: SAS.

Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G., Seynaeve, C., van Geel, A. N., Tilanus, M. M., Bartels, C. C., Verhoog, L. C., Brekelmans, C. T., Burger, C. W., & Niermeijer, M. F. (2002). One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: Emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat, 73, 97–112.PubMedCrossRef

Meijers-Heijboer, H., Brekelmans, C. T., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., Crepin, E., van den Ouweland, A. W., van Geel, B., & Klijn, J. G. (2003). Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol, 21, 1675–1681.PubMedCrossRef

Meijers-Heijboer, H., van Geel, B., van Putten, W. L., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B., Bartels, C. C., Verhoog, L. C., van den Ouweland, A. M., Niermeijer, M. F., Brekelmans, C. T., & Klijn, J. G. (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med, 345, 159–164.PubMedCrossRef

Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClure, M., Frye, C., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Bogden, R., Dayananth, P., Ward, J., Tonin, P., Narod, S., Bristow, P. K., Norris, F. H., Helvering, L., Morrison, P., Rosteck, P., Lai, M., Barrett, J. C., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Wiseman, R., Kamb, A., & Skolnick, M. H. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66–71.PubMedCrossRef

O’Malley, M. S., Earp, J. A., Hawley, S. T., Schell, M. J., Mathews, H. F., & Mitchell, J. (2001). The association of race/ethnicity, socioeconomic status, and physician recommendation for mammography: Who gets the message about breast cancer screening? Am J Public Health, 91, 49–54.PubMed

Offit, K., Robson, M., & Schrag, D. (2001). Prophylactic mastectomy in carriers of BRCA mutations. N Engl J Med, 345, 1498–1499.PubMedCrossRef

Orleans, C. T., Boyd, N. R., Bingler, R., Sutton, C., Fairclough, D., Heller, D., McClatchey, M., Ward, J. A., Graves, C., Fleisher, L., & Baum, S. (1998). A self-help intervention for African American smokers: Tailoring cancer information service counseling for a special population. Prev Med, 27, S61–S70.PubMedCrossRef

Paskett, E. D., Tatum, C., Rushing, J., Michielutte, R., Bell, R., Foley, K. L., Bittoni, M., & Dickinson, S. (2004). Racial differences in knowledge, attitudes, and cancer screening practices among a triracial rural population. Cancer, 101, 2650–2659.PubMedCrossRef

Rauscher, G. H., Hawley, S. T., & Earp, J. A. (2005). Baseline predictors of initiation vs. maintenance of regular mammography use among rural women. Prev Med, 40, 822–830.PubMedCrossRef

Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., Van't Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., Daly, M. B., Olopade, O. I., & Weber, B. L. (2004). Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. J Clin Oncol, 22, 1–8.CrossRef

Safran, D. G., Taira, D. A., Rogers, W. H., Kosinski, M., Ware, J. E., & Tarlov, A. R. (1998). Linking primary care performance to outcomes of care. J Fam Pract, 47, 213–220.PubMed

Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., Norton, L., & Offit, K. (2002). Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol, 20, 1260–1268.PubMedCrossRef

Schwartz, M. D., Kaufman, E., Peshkin, B. N., Isaacs, C., Hughes, C., DeMarco, T., Finch, C., & Lerman, C. (2003). Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol, 21, 4034–4041.PubMedCrossRef

Wainberg, S., & Husted, J. (2004). Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomark Prev, 13, 1989–1995.

Titel: Risk Reduction Behaviors and Provider Communication Following Genetic Counseling and BRCA1 Mutation Testing in an African American Kindred
verfasst von: Anita Yeomans Kinney
Sara Ellis Simonsen
Bonnie Jeanne Baty
Diptasri Mandal
Susan L. Neuhausen
Kate Seggar
Richard Holubkov
Lindsey Bloor
Ken Smith
Publikationsdatum: 01.08.2006
Verlag: Springer US
Erschienen in: Journal of Genetic Counseling / Ausgabe 4/2006
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-006-9026-7

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Internistische Arzneimitteltherapie Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Risk Reduction Behaviors and Provider Communication Following Genetic Counseling and BRCA1 Mutation Testing in an African American Kindred

Abstract

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2006

Supervision of Psychosocial Skills in Genetic Counseling

Predictive Testing of Eighteen Year Olds: Counseling Challenges

Genetic Testing: Care, Consent and Liability. By Neil F. Sharpe and Ronald F. Carter. Wiley-Liss, Hoboken, New Jersey, 2006, 594 pp., Hardback.

Games in Clinical Genetic Counseling Supervision

What Do We Tell the Children? Contrasting the Disclosure Choices of Two HD Families Regarding Risk Statusand Predictive Genetic Testing

Correlates of Depressive Symptoms Among Women Seeking Cancer Genetic Counseling and Risk Assessment at a High-Risk Cancer Clinic

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie